FDA panel votes against panobinostat as add-on therapy for multiple myeloma

SILVER SPRING, MD. – The majority of a Food and Drug Administration advisory panel agreed that the risk-benefit profile of panobinostat as add-on treatment to bortezomib and dexamethasone did not...